Pfizer (PFE) recently reported a revenue decline tied to weaker COVID product sales and a US$4.4b impairment charge, while ...

Pfizer's 7% dividend yield ranks among the highest in the healthcare sector, nearly triple the average of the S&P 500. The payout ratio has improved to 89% from over 100% in recent quarters, but ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Value Stocks with Highest Dividends. On April 13, UBS Group AG raised its price recommendation on Pfizer Inc. (NYSE:PFE) to $27 from $25. It maintained ...

Pfizer is seeking drug development partnerships with Chinese biotech companies as local players gain ground on Western peers.

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

On April 13, UBS Group AG raised its price recommendation on Pfizer Inc. (NYSE:PFE) to $27 from $25. It maintained a Neutral ...

Pfizer possesses several qualities that make it attractive when market volatility is high. The stock has a low forward earnings multiple and a higher -- yet still attractive -- EV-to-EBITDA ratio.

Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...